Literature DB >> 28687111

Emerging Therapies in Hereditary Angioedema.

Meng Chen1, Marc A Riedl2.   

Abstract

Remarkable progress has been made in the treatment of bradykinin-mediated angioedema with the advent of multiple new therapies. Patients now have effective medications available for prophylaxis and treatment of acute attacks. However, hereditary angioedema is a burdensome disease that can lead to debilitating and dangerous angioedema episodes associated with significant costs for individuals and society. The burden of treatment must be addressed regarding medication administration difficulties, treatment complications, and adverse side effects. New therapies are being investigated and may offer solutions to these challenges. This article reviews the emerging therapeutic options for the treatment of HAE.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angioedema; Bradykinin; C1 esterase inhibitor; Emerging therapies; Factor XII; Kallikrein

Mesh：

Substances：

Year:  2017        PMID： 28687111      PMCID： PMC5585075          DOI： 10.1016/j.iac.2017.03.003

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN： 0889-8561            Impact factor:   3.479


  13 in total

1.  Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab.

Authors:  Mark F Sands; Jessica W Blume; Stanley A Schwartz
Journal:  J Allergy Clin Immunol       Date:  2007-10       Impact factor: 10.793

2.  A phase 1 study investigating DX-2930 in healthy subjects.

Authors:  Yung Chyung; Bradley Vince; Ryan Iarrobino; Dan Sexton; Jon Kenniston; Ryan Faucette; Chris TenHoor; Leslie E Stolz; Chris Stevens; Joseph Biedenkapp; Burt Adelman
Journal:  Ann Allergy Asthma Immunol       Date:  2014-06-26       Impact factor: 6.347

3.  Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab.

Authors:  Antonie von Websky; Kristian Reich; Volker Steinkraus; Kristine Breuer
Journal:  J Dtsch Dermatol Ges       Date:  2013-04-10       Impact factor: 5.584

Review 4.  HAE Pathophysiology and Underlying Mechanisms.

Authors:  Bruce L Zuraw; Sandra C Christiansen
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

5.  Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.

Authors:  Alexey S Revenko; Dacao Gao; Jeff R Crosby; Gourab Bhattacharjee; Chenguang Zhao; Chris May; David Gailani; Brett P Monia; A Robert MacLeod
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

6.  Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.

Authors:  Marc A Riedl; William R Lumry; H Henry Li; Aleena Banerji; Jonathan A Bernstein; Murat Ba; Janne Bjrkander; Markus Magerl; Marcus Maurer; Kevin Rockich; Hongzi Chen; Jennifer Schranz
Journal:  Allergy Asthma Proc       Date:  2016-11       Impact factor: 2.587

7.  Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12.

Authors:  Gourab Bhattacharjee; Alexey S Revenko; Jeffrey R Crosby; Chris May; Dacao Gao; Chenguang Zhao; Brett P Monia; A Robert MacLeod
Journal:  Nucleic Acid Ther       Date:  2013-04-12       Impact factor: 5.486

Review 8.  A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).

Authors:  Konrad Bork
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

9.  Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.

Authors:  B L Zuraw; M Cicardi; H J Longhurst; J A Bernstein; H H Li; M Magerl; I Martinez-Saguer; S M M Rehman; P Staubach; H Feuersenger; R Parasrampuria; J Sidhu; J Edelman; T Craig
Journal:  Allergy       Date:  2015-08-11       Impact factor: 13.146

10.  Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study.

Authors:  Inmaculada Martinez-Saguer; Marco Cicardi; Chiara Suffritti; Eva Rusicke; Emel Aygören-Pürsün; Hildegard Stoll; Tanja Rossmanith; Annette Feussner; Uwe Kalina; Wolfhart Kreuz
Journal:  Transfusion       Date:  2013-11-24       Impact factor: 3.157
View more
  6 in total

1.  Acute Presentation of Undiagnosed Hereditary Angioedema of the Larynx: Averting Death.

Authors:  Nikhil Rajan; Vidhu Sharma; Sourabha Kumar Patro; Amit Goyal
Journal:  Turk Arch Otorhinolaryngol       Date:  2020-12-01

2.  Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.

Authors:  William R Lumry; Karsten Weller; Markus Magerl; Aleena Banerji; Hilary J Longhurst; Marc A Riedl; Hannah B Lewis; Peng Lu; Giovanna Devercelli; Gagan Jain; Marcus Maurer
Journal:  Allergy       Date:  2020-12-24       Impact factor: 13.146

3.  Pregnancy-Induced Exacerbation of Hereditary Angioedema in a Multiparous Caucasian Female.

Authors:  Praveen Sankrithi; Kunal Shah; Celina C Bernabe
Journal:  Cureus       Date:  2020-05-07

4.  IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production.

Authors:  Jason D Ferrone; Gourab Bhattacharjee; Alexey S Revenko; Thomas A Zanardi; Marshelle S Warren; Frederick J Derosier; Nicholas J Viney; Nguyen C Pham; Gwendolyn E Kaeser; Brenda F Baker; Eugene Schneider; Steven G Hughes; Brett P Monia; A Robert MacLeod
Journal:  Nucleic Acid Ther       Date:  2019-02-28       Impact factor: 5.486

5.  Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.

Authors:  Marc A Riedl; Marcus Maurer; Jonathan A Bernstein; Aleena Banerji; Hilary J Longhurst; H Henry Li; Peng Lu; James Hao; Salomé Juethner; William R Lumry
Journal:  Allergy       Date:  2020-07-06       Impact factor: 13.146

6.  A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.

Authors:  Ivan Ivanov; Anton Matafonov; Mao-Fu Sun; Bassem M Mohammed; Qiufang Cheng; S Kent Dickeson; Suman Kundu; Ingrid M Verhamme; Andras Gruber; Keith McCrae; David Gailani
Journal:  Blood       Date:  2018-12-27       Impact factor: 25.476
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.